Reuters logo
3 months ago
BRIEF-Cerecor reports topline data from a NIH sponsored proof-of-concept trial of CERC-501 in treatment-resistant depression
May 1, 2017 / 1:06 PM / 3 months ago

BRIEF-Cerecor reports topline data from a NIH sponsored proof-of-concept trial of CERC-501 in treatment-resistant depression

1 Min Read

May 1 (Reuters) - Cerecor Inc

* Cerecor reports encouraging topline data from a NIH sponsored proof-of-concept trial of Cerc-501 in treatment-resistant depression

* Cerecor Inc - CERC-501 generally well-tolerated with no serious adverse events reported and no discontinuations due to adverse events with CERC-501

* Clinically meaningful improvements observed at day 3 from proof-of-concept trial of CERC-501 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below